World's Best Scientists 2026 revealed!
Award Badge
Medicine
France
2023

D-Index & Metrics

Medicine

D-Index
125
Citations
82293
World Ranking
3021
National Ranking
78

Research.com Recognitions

  • 2023 - Research.com Medicine in France Leader Award

Overview

Michel Ducreux is affiliated with the Institut Gustave Roussy in France and has contributed extensively to the field of medicine, particularly focusing on oncology. Their research spans a broad spectrum, including hepatology, pulmonary and respiratory medicine, and surgery.

The scientist has published prominently in several venues, with the most frequent being:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • European Journal of Cancer
  • ESMO Open
  • Cancers

Michel Ducreux's main fields of study center on medicine with a major emphasis on oncology, supported by subfields such as:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Surgery
  • Hepatology
  • Cancer Research

Their research covers key topics including:

  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Genomics and Diagnostics
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Gastric Cancer Management and Outcomes
  • Genetic factors in colorectal cancer

Michel Ducreux has co-authored numerous papers with several frequent collaborators, among them:

  • Antoine Hollebecque
  • Alice Boilève
  • Cristina Smolenschi
  • Maximiliano Gelli
  • Valérie Boige

Selected recent papers include:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, 2020, New England Journal of Medicine
  • Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma, 2021, Journal of Hepatology
  • Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial, 2020, The Lancet. Gastroenterology & hepatology
  • Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology

Best Publications

  • FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

    Thierry Conroy;Françoise Desseigne;Marc Ychou;Olivier Bouché

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

    Astrid Lièvre;Jean-Baptiste Bachet;Delphine Le Corre;Valérie Boige

  • EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

    Josep M. Llovet;Michel Ducreux;Riccardo Lencioni;Adrian M. Di Bisceglie

  • Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

    Jean-Pierre Gérard;Thierry Conroy;Franck Bonnetain;Olivier Bouché

  • KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

    Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre

  • Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M. Ducreux;M. Ducreux;A. Sa. Cuhna;C. Caramella;A. Hollebecque

  • Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

    Marc Peeters;Timothy Jay Price;Andrés Cervantes;Alberto F. Sobrero

  • Immunogenic death of colon cancer cells treated with oxaliplatin.

    A. Tesniere;F. Schlemmer;F. Schlemmer;F. Schlemmer;V. Boige;O. Kepp;O. Kepp;O. Kepp

  • Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

    Christophe Louvet;R. Labianca;P. Hammel;G. Lledo

  • A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.

    P. Rougier;A. Adenis;M. Ducreux;M. de Forni

  • Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

    Pierre Laurent-Puig;Anne Cayre;Gilles Manceau;Emmanuel Buc

  • Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group

    Udo Vanhoefer;Philippe Rougier;Hansjochen Wilke;Michel P. Ducreux

  • Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?

    René Adam;Dennis A. Wicherts;Robbert J. de Haas;Oriana Ciacio

  • Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

    Theo Ruers;Frits Van Coevorden;Cornelis J. A. Punt;Jean-Pierre E. N. Pierie

  • Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

    E Mitry;E Baudin;M Ducreux;J C Sabourin

  • Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.

    D. Elias;F. Blot;A. El Otmany;S. Antoun

  • Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial

    Gilles Pelletier;Michel Ducreux;Monique Luboinski

  • Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year.

    Thierry de Baere;Dominique Elias;Clarisse Dromain;Mostafa Gamal El Din

Frequent Co-Authors

Valérie Boige
Valérie Boige Institut Gustave Roussy
David Malka
David Malka Institut Mutualiste Montsouris
Dominique Elias
Dominique Elias Institut Gustave Roussy
Eric Baudin
Eric Baudin Institut Gustave Roussy
Olivier Bouché
Olivier Bouché CHU de Reims
Thierry de Baere
Thierry de Baere Institut Gustave Roussy
Philippe Rougier
Philippe Rougier University of Nantes
Pierre Duvillard
Pierre Duvillard Institut Gustave Roussy
Sophie Leboulleux
Sophie Leboulleux University of Geneva

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA is a transformative journey, but students often consider alternative or complementary pathways in healthcare. Flexible online options have made specialized training and career advancement more accessible for diverse learners.

For example, accelerated healthcare programs allow students to quickly gain administrative expertise that is critical for leadership roles in hospitals and clinics. If you are already a nurse and want to step into advanced practice, exploring adn to fnp bridge programs can help you become a Family Nurse Practitioner with an efficient online pathway.

Additionally, programs in nutrition—like an online nutrition degree—are ideal for students interested in preventive health and dietary science. Those aiming for executive positions can build on their credentials through accredited mha programs, equipping themselves for strategic health management roles.

These options provide diverse opportunities for anyone interested in contributing to healthcare beyond direct patient care, all while enjoying the flexibility of online study.

Best Scientists Citing Michel Ducreux

Trending Scientists